Abrocitinib

Generic name
Abrocitinib
Brand name
ATC Code
D11AH08
Compare …

Abrocitinib

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

Based on population pharmacokinetic analysis, there was no clinically relevant difference in mean exposures to abrocitinib at steady-state between adolescent patients and adults with normal body weights.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Moderate to severe constitutional eczema
  • Oral
    • ≥ 12 years and 25 up to 59 kg
      • Start 100 mg/day in 1 dose When insufficient respons, increase dose to 200 mg/day.

      • Consider discontinuing treatment if no response has occurred after 24 weeks.

    • ≥ 12 years and ≥ 59 kg
      • 100 - 200 mg/day in 1 dose Reduce dosage to 100 mg/day once symptoms are under control..

      • Consider discontinuing treatment if no response has occurred after 24 weeks.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

The safety profile in adolescents is similar to that of the adult population.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

OTHER DERMATOLOGICAL PREPARATIONS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Other dermatologicals
D11AX
Agents for dermatitis, excluding corticosteroids
D11AH05
D11AH02
D11AH01
D11AH07
OTHER DERMATOLOGICALS
D11AX

Reference

  1. Pfizer Europe MA EEIG, SmPC Cibinqo (EU/1/21/1593) Rev 8, 8-04-2024, www.ema.europa.eu

Changes

Therapeutic Drug Monitoring


Overdose